Express Scripts will make an AbbVie drug the exclusive option for patients with the most common form of hepatitis C. The move will help the drug maker take market share from Gilead, maker of Sovaldi.
via WSJ.com: US Business http://ift.tt/1zTKhFa
via WSJ.com: US Business http://ift.tt/1zTKhFa
Nessun commento:
Posta un commento